For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 48,936 | |||
| General and administrative | 13,789 | |||
| Credit loss - related party accounts receivable | 0 | |||
| Total operating expenses | 62,725 | |||
| Loss from operations | -62,725 | |||
| Unrealized loss on short-term investments | -5 | |||
| Interest and dividend income | 5,139 | |||
| Total other income, net | 5,134 | |||
| Net loss | -57,591 | |||
| Basic EPS | -2.93 | |||
| Diluted EPS | -2.93 | |||
| Basic Average Shares | 19,624,626 | |||
| Diluted Average Shares | 19,624,626 | |||
Aardvark Therapeutics, Inc. (AARD)
Aardvark Therapeutics, Inc. (AARD)